Utah Medical Q3 revenue falls 12% to $8.6 million; diluted EPS rises 6.8% to $0.876
Utah Medical Products reported third-quarter 2026 revenue of $8.6 million, down 12.1% from $9.8 million a year earlier, as sales to two former major customers ended. Diluted EPS rose 6.8% to $0.876 on lower share count and higher operating income, but nine-month diluted EPS fell 5.3% to $2.537. Management projects a full-year 2026 sales decline of close to 7%, compared with the 12% year-to-date decline through September.
Key points
- Q3 2026 revenue was $8.6 million, down 12.1% from $9.8 million in Q3 2025; nine-month revenue was $25.9 million, down 12.2%
- Q3 2026 net income was $2.8 million, up 5.9%; nine-month net income was $8.1 million, down 7.4%
- Management's 2026 full-year sales projection is a decline close to 7%, versus the 12% year-to-date decline
- Cash and investments were $85.2 million at September 30, 2026, and the company reported no debt
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.